GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for OASIS 4 - CURE

OASIS 4 - CURE

Official Title

The Clopidogrel in unstable angina to prevent recurrent events

Status

Completed

Overview

To evaluate the efficacy and safety of clopidogrel when given with aspirin patients with non- ST-segment elevation acute coronary syndromes. Clopidogrel had beneficial, however, there was an increased risk of major bleeding. The findings of the CURE trial led to widespread use of clopidogrel in non -ST segment elevation ACS patients, modification of practice guidelines and regulatory approvals in many countries around the world. Clopidogrel has become an established therapy in these patients and one of the most commonly used drugs in ACS.

Study Design

Randomized, controlled trial.

Primary Endpoint

First co-primary outcome: the composite of death from CV causes, nonfatal MI, or stroke; Second co- primary outcome; the composite of the first primary outcome or refractory ischemia. Secondary outcomes: severe ischemia, heart failure, and the need for revascularization. Safety-related outcomes: bleeding complications, categorized as life-threatening, major or minor. All primary outcomes and life-threatening and major bleeding complications were adjudicated

Number of Patients

12562

Number of Sites

482

Number of Countries

28

Study Period

1998–2001

Principal Investigator

Salim Yusuf

Program Manager

Not Applicable

Research Coordinator

Susan Chrolavicius

Key Publications

  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
  • Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527-33.